Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer


Introducing the RADAR studies

Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer. He covers when to use these tools by examining the published data, specifically the RADAR 1 and 3 studies. The RADAR (radiographic assessments for detection of advanced recurrence) group, are a team of experts, including Dr Koo, who have published articles pertinent to prostate cancer imaging. The initial paper of RADAR 1 reviewed imaging guidelines with associated clinical validation studies for metastatic prostate cancer. It provided recommendations for clinical practice to improve early detection of metastatic disease. RADAR III focuses on updates regarding next generation imaging for improved guidance.

Important findings for imaging metastatic prostate cancer

In this video and associated slides, Dr Koo details the RADAR 1 and 3 recommendations, comparing conventional imaging to advanced PET imaging for detection of metastatic disease in prostate cancer. Prostate cancer PET detection rates as a function of PSA in patients with biochemical recurrence are addressed. The suitability of radiotracers for next generation imaging is discussed, and how to approach different patient groups. Lastly, what test to use based on availability, accounting for location and coverage by MEDICARE. View the video and slides provided as part of our educational resources and practical guidance for medical oncologists and urologists.

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr Koo is an active member of multiple societies and serves on the Scientific Program Committee for the Radiological Society of North America, Nuclear Radiology Certifying Exam Committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  He is also Chair of the Prostate Cancer Working Group at the SNMMI and was a member of the RADAR I and II working groups. Dr Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.  

Dr Phillip Koo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Blue Earth, Janssen, Lantheus, Merck and Novartis. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
Precision oncology in prostate and gastric cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
podcast Podcast

Episode

2

of 2

episode
Oncology 
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Medical experts discuss how to approach sequencing in clinical practice

Experts
Prof. Arndt Vogel, Dr Lorenza Rimassa, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery Global Liver Institute
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
Testing to treatment of BRAF-mutant metastatic NSCLC

Medical experts share their insights on testing and treatment

Experts
Prof. David Planchard, Dr Federico Cappuzzo
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. This content is intended for HCPs outside the UK & ROI only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
HCC podcast series part 1: The use of IO in unresectable HCC

Medical experts discuss safety and efficacy of IO and IO combinations, clinical trial data, and best practice

Experts
Dr Rachna Shroff, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.